Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 1.00 |
| ▸ | BACE1 | P56817 | 5/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 1.00 |
| ▸ | MMP7 | P09237 | 5/20 | 1.00 |
| ▸ | MMP14 | P50281 | 5/20 | 1.00 |
| ▸ | BCL2 | P10415 | 4/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | PGD | P52209 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | PGAM1 | P18669 | 2/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epigalocatechin Gallate SCHEMBL29389587 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL30977114 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL30909383 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL10198783 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL14423426 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL35258 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL49461 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL13624466 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL8426376 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL29410018 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380633-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023191839-A9 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023191839-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4719497-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | Rayzebio, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12514939-B2 | Stable radiopharmaceutical compositions and uses thereof | ALPHA-9 ONCOLOGY, INC. (CA) | 2026-01-06 | — | — | US | disclosed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4618965-A1 | NOVEL OPHTHALMIC FORMULATION | Fertis India Pvt. Ltd. (IN) | 2025-09-24 | — | — | EP | disclosed |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ALPHA-9 ONCOLOGY INC. (CA) | 2025-08-14 | — | — | US | disclosed |
| WO-2024248823-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | RAYZEBIO, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024249352-A1 | METHODS FOR TREATING SSTR POSITIVE CANCER | RAYZEBIO, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118831183-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024158981-A1 | COMPOSITIONS AND METHODS FOR REDUCING THE RATE OF TYPE 1 DIABETES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-4380633-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118103078-A | Stabilized compositions of radionuclides and uses thereof | 瑞择生物公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023191839-A9 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023191839-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-3472303-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2022-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RCN1, RABL6, QPCT | DYRK1A 3164/4885BACE1 2193/4885MMP2 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.